These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21128645)

  • 1. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
    Prime ME; Courtney SM; Brookfield FA; Marston RW; Walker V; Warne J; Boyd AE; Kairies NA; von der Saal W; Limberg A; Georges G; Engh RA; Goller B; Rueger P; Rueth M
    J Med Chem; 2011 Jan; 54(1):312-9. PubMed ID: 21128645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
    Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
    J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
    Fancelli D; Moll J; Varasi M; Bravo R; Artico R; Berta D; Bindi S; Cameron A; Candiani I; Cappella P; Carpinelli P; Croci W; Forte B; Giorgini ML; Klapwijk J; Marsiglio A; Pesenti E; Rocchetti M; Roletto F; Severino D; Soncini C; Storici P; Tonani R; Zugnoni P; Vianello P
    J Med Chem; 2006 Nov; 49(24):7247-51. PubMed ID: 17125279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
    Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
    Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
    Pevarello P; Fancelli D; Vulpetti A; Amici R; Villa M; Pittalà V; Vianello P; Cameron A; Ciomei M; Mercurio C; Bischoff JR; Roletto F; Varasi M; Brasca MG
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1084-90. PubMed ID: 16290148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
    Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
    J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.
    Kerekes AD; Esposite SJ; Doll RJ; Tagat JR; Yu T; Xiao Y; Zhang Y; Prelusky DB; Tevar S; Gray K; Terracina GA; Lee S; Jones J; Liu M; Basso AD; Smith EB
    J Med Chem; 2011 Jan; 54(1):201-10. PubMed ID: 21128646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
    Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
    Soncini C; Carpinelli P; Gianellini L; Fancelli D; Vianello P; Rusconi L; Storici P; Zugnoni P; Pesenti E; Croci V; Ceruti R; Giorgini ML; Cappella P; Ballinari D; Sola F; Varasi M; Bravo R; Moll J
    Clin Cancer Res; 2006 Jul; 12(13):4080-9. PubMed ID: 16818708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.
    Curtin ML; Heyman HR; Frey RR; Marcotte PA; Glaser KB; Jankowski JR; Magoc TJ; Albert DH; Olson AM; Reuter DR; Bouska JJ; Montgomery DA; Palma JP; Donawho CK; Stewart KD; Tse C; Michaelides MR
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4750-5. PubMed ID: 22695126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.
    Li X; Lu X; Xing M; Yang XH; Zhao TT; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3589-93. PubMed ID: 22572580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
    Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
    J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
    Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
    J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
    Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.
    Coumar MS; Leou JS; Shukla P; Wu JS; Dixit AK; Lin WH; Chang CY; Lien TW; Tan UK; Chen CH; Hsu JT; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2009 Feb; 52(4):1050-62. PubMed ID: 19140666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile.
    Chiang CC; Lin YH; Lin SF; Lai CL; Liu C; Wei WY; Yang SC; Wang RW; Teng LW; Chuang SH; Chang JM; Yuan TT; Lee YS; Chen P; Chi WK; Yang JY; Huang HJ; Liao CB; Huang JJ
    J Med Chem; 2010 Aug; 53(16):5929-41. PubMed ID: 20681538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.
    Bavetsias V; Crumpler S; Sun C; Avery S; Atrash B; Faisal A; Moore AS; Kosmopoulou M; Brown N; Sheldrake PW; Bush K; Henley A; Box G; Valenti M; de Haven Brandon A; Raynaud FI; Workman P; Eccles SA; Bayliss R; Linardopoulos S; Blagg J
    J Med Chem; 2012 Oct; 55(20):8721-34. PubMed ID: 23043539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
    Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a potent and selective aurora kinase inhibitor.
    Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.